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The neurodegenerative disease Spinocerebellar ataxia type 1 (SCA1) is a polyglutamine 
expansion disorder characterized by the death of Purkinje neurons in the brain. In this issue, 
Serra et al. (2006) implicate the impaired function of the orphan nuclear receptor RORα in 
SCA1 pathogenesis. Their intriguing results suggest that derailing a transcription program 
during embryonic development may render adult neurons more susceptible to toxic insults.The mechanisms underlying the 
selective vulnerability of neurons in 
neurodegenerative disorders, such 
as Alzheimer disease (AD), Parkin-
son’s disease (PD), prion diseases, 
and amyotrophic lateral sclerosis 
(ALS), remain enigmatic. Inherited 
subtypes of these diseases exem-
plify this conundrum, as AD, PD, and 
ALS can result from dominant gene 
mutations whose protein products 
are widely expressed throughout the 
central nervous system (CNS). For 
the polyglutamine (polyQ) expan-
sion diseases, of which there are 
nine—spinobulbar muscular atrophy 
(SBMA), Huntington’s disease (HD), 
dentatorubral-pallidoluysian atrophy 
(DRPLA), and six forms of spinocer-
ebellar ataxia (SCA1, 2, 3, 6, 7, and 
17)—different regions of the CNS are 
affected in each disorder, despite 
widespread, overlapping expres-
sion patterns of the different pro-
teins encoded by the disease genes. 
Selective vulnerability of neurons in 
polyQ diseases has been attributed 
to restricted expression of an inter-
acting protein partner, a proteolytic 
cleavage enzyme, or a posttransla-
tional modification that acts upon 
or with the polyQ disease protein 
to initiate the pathogenic cascade. 
Thus, defining the “interactome” of 
disease-associated proteins through 
yeast two-hybrid assays or mass 
spectrometry or determining dis-
ease protein functional domains and 
site-specific modifications are useful methods for dissecting this problem. 
In many cases, however, validat-
ing the relevance of the implicated 
interacting protein or modification 
pathway to the disease process has 
proven difficult.
In this issue of Cell, Harry Orr’s 
group presents results from a study 
of SCA1 pathogenesis in a mouse 
model prompted by noting an unex-
pected correlation between disease 
severity and timing of expression 
of the mutant protein Ataxin 1 dur-
ing development (Serra et al., 2006). 
SCA1 is an autosomal dominant 
disease of cerebellar degeneration 
characterized by gait ataxia, slurred 
speech, and oculomotor abnormali-
ties. The cause of SCA1 is the expan-
sion of a variably sized CAG repeat 
in ataxin-1 that results in accumula-
tion of mutant Ataxin 1, which is toxic 
to Purkinje cells. SCA1 transgenic 
mice that overexpress the polyQ-
expanded Ataxin 1 protein only in 
cerebellar Purkinje neurons—accom-
plished by placing the mutant ataxin-
1 under the control of the Purkinje cell 
protein-2 (Pcp-2) promoter (Burright 
et al., 1995)—are a very useful model 
for testing hypotheses about polyQ 
toxicity. Interestingly, the B04 strain 
of Pcp-2 SCA1 mice display a more 
severe ataxia phenotype than the B05 
strain, despite lower levels of mutant 
Ataxin 1 expression in B04 mice. One 
difference that could account for this 
phenotypic discrepancy is the onset 
of transgene expression. In the B04 Cell 127, Novemice, mutant Ataxin 1 expression 
begins on postnatal day 2, whereas 
in the B05 mice, it begins between 
postnatal days 10 and 14.
To test this hypothesis, Serra et al. 
(2006) took advantage of an inducible 
Pcp2–SCA1 “tet-off” mouse model 
(Zu et al., 2004). They compared 
Pcp2 SCA1 mice with the transgene 
turned on during the critical first 3 
weeks of postnatal development with 
Pcp2 SCA1 mice where the transgene 
was not turned on until after postna-
tal development. Notably, Pcp2 SCA1 
mice that did not express mutant 
Ataxin 1 protein during this develop-
mental window appeared normal with 
respect to behavior and cerebellar 
histology, in contrast to Pcp2 SCA1 
mice with the transgene turned on 
during postnatal development. To 
determine the mechanistic explana-
tion for this finding, Serra et al. (2006) 
turned to the well-characterized 
mouse cerebellar mutant known as 
staggerer. The staggerer mouse dis-
plays, among a wide range of other 
non-neural abnormalities, a profound 
cell-autonomous developmental loss 
of cerebellar Purkinje cells (Sidman et 
al., 1962). The cause of its cerebel-
lar defect is an intragenic deletion 
in the retinoic acid-related orphan 
receptor α (RORα) gene (Hamilton 
et al., 1996). The connection with 
RORα became clear when Serra et al. 
(2006) compared data from previous 
microarray and subtractive hybridiza-
tion studies of presymptomatic Pcp2 mber 17, 2006 ©2006 Elsevier Inc. 669
SCA1 mice with gene profil-
ing data from staggerer mice 
(Gold et al., 2003). This latter 
study yielded an extensive 
list of RORα-regulated target 
genes. The overlap of the pre-
viously identified SCA1 gene 
list with the RORα regulon led 
the Orr group to evaluate the 
role of RORα in SCA1 disease 
pathogenesis. They observed 
a reduction in the amount of 
RORα protein when the SCA1 
transgene was expressed 
and demonstrated a correla-
tion between RORα protein 
levels and timing of transgene 
activation in their SCA1 mice. 
Using coimmunoprecipitation 
from cerebellar lysates, Serra 
et al. (2006) found that RORα 
and Ataxin 1 interact; how-
ever, these proteins do not 
interact directly in vitro. A pre-
vious study had indicated that 
a transcription coactivator 
known as Tip60 occupied the 
promoters of genes altered in 
presymptomatic SCA1 trans-
genic mice (Gold et al., 2003). 
The fact that Tip60 has been 
shown to be in a complex with RORα 
at Purkinje cell-specific promoters 
led Serra et al. (2006) to examine the 
role of Tip60. They found that Tip60 
not only coimmunoprecipitated 
Ataxin 1 but also directly interacted 
with Ataxin 1. Furthermore, Serra 
et al. (2006) mapped the interac-
tion between these two proteins to 
the 425–527 amino acid segment of 
the Ataxin 1 protein. This region has 
been implicated in delayed disease 
progression (Skinner et al., 2002), 
suggesting that loss of the putative 
Tip60 interaction may ameliorate 
polyQ-Ataxin 1 neurotoxicity.
There are many aspects of this 
intriguing study that deserve consid-
eration. First, there is an overwhelm-
ingly strong connection between 
altered expression of RORα target 
genes and cerebellar degeneration. 
That altered expression of RORα 
target genes could account for cer-
ebellar Purkinje cell degeneration 
in SCA1 is a plausible and appeal-
ing hypothesis and is supported by 
the observation that partial loss of 
RORα enhances the pathogenicity 
of mutant Ataxin 1 in the transgenic 
mice (Serra et al., 2006). Of course, 
it will be important to test if the SCA1 
phenotype can be rescued by trans-
genic overexpression of RORα, as 
this would highlight the importance 
of RORα expression modulation as a 
desirable therapeutic goal. Although 
the RORα hypothesis is seductively 
straightforward, the mechanistic 
basis of how the Tip60–Ataxin 1 
interaction disrupts RORα func-
tion remains to be clarified (Figure 
1). Tip60’s interaction with Ataxin 1 
appeared to be dependent on polyQ 
length in immunoprecipitation exper-
iments with cerebellar tissue lysates 
and cell culture extracts; however, no 
evidence for polyQ length depend-
ence was found during in vitro pull-
down assays. This pattern of results 
could imply a tripartite interaction 
involving another protein upon which 
the polyQ length effect depends. 
Furthermore, Serra et al. (2006) pro-
pose that RORα recovery, 
after turning off polyQ-Ataxin 
1, occurs at the protein level 
in the absence of substantial 
transcriptional upregulation. 
It would appear that stabi-
lization of RORα by Tip60 
may be driving the restora-
tion of RORα protein, which 
is required for recovery from 
neurotoxicity mediated by 
polyQ-Ataxin 1. Defining the 
molecular players and inter-
actions in the RORα-Tip60-
Ataxin 1 complex may clarify 
the true mechanistic basis of 
the observed effects. Further-
more, as the Tip60 protein 
has intrinsic histone acetyl-
transferase (HAT) activity, the 
effect of Ataxin 1 binding upon 
Tip60 HAT activity should be 
considered. Decreased RORα 
target gene expression could 
be due to impaired chroma-
tin remodeling secondary to 
polyQ-dependent inhibition 
of Tip60 HAT activity. Such a 
scenario has been proposed 
for interference of GCN5 HAT 
activity by polyQ-Ataxin 7 
in the STAGA complex during reti-
nal degeneration in SCA7 (Palhan 
et al., 2005). If impaired Tip60 HAT 
activity is involved, then histone 
deacetylase inhibitors could be used 
to treat SCA1 cerebellar degenera-
tion. Finally, it is interesting to note 
that Tip60 has been implicated in 
regulating DNA repair and immune 
response pathways through its pro-
posed acetylation of the ataxia tel-
angiectasia mutant (ATM) protein 
kinase (Sun et al., 2005). In light of 
the coexistence of cerebellar degen-
eration, immunodeficiency, and 
blood vessel disease in both stag-
gerer mice and ataxia telangiectasia 
patients, it is tempting to speculate 
that interference with Tip60 activity 
could contribute to both the neu-
ral and non-neural abnormalities in 
these two conditions.
One key implication of the Serra et 
al. (2006) study is that adult neurons 
can “remember” untoward events 
that occur during key developmental 
windows. Indeed, as long as induc-
Figure 1. Mutant Ataxin 1 and RORα Transactivation
(Left) Wild-type Ataxin 1 normally binds to Tip60, and this 
binding permits a productive interaction of Tip60 with RORα. 
This interaction may stabilize RORα or facilitate transactiva-
tion of RORα target genes.
(Right) When bound to polyQ-expanded Ataxin 1, Tip60 no 
longer engages in a productive interaction with RORα. The al-
tered Tip60-RORα interaction may prevent RORα target gene 
expression because of an improperly assembled transcription 
activation complex, or due to RORα destabilization and sub-
sequent degradation.670 Cell 127, November 17, 2006 ©2006 Elsevier Inc.
tion of mutant Ataxin 1 protein is 
delayed until after postnatal day 14, 
it would appear that Purkinje cell 
neurons are much better equipped 
to tolerate exposure to toxic mis-
folded proteins. It is very intriguing 
that the window is so narrow, as the 
presented data suggest that large 
amounts of Ataxin 1 protein do not 
appear until postnatal day 10. None-
theless, the presence of mutant pro-
tein for scarcely 5 days is sufficient 
to elicit this profound toxic effect. In 
the polyQ repeat diseases HD and 
SBMA, it has been proposed that 
the normal function of the disease 
protein is required for preventing or 
retarding progression of the degen-
erative phenotype (Cattaneo et al., 
2005; Thomas et al., 2006). As both 
the huntingtin protein and the andro-
gen receptor protein appear impor-
tant for neurons during develop-
ment, diminished normal function of At synapses, neurotransmission is 
mediated by exocytosis of synap-
tic vesicles that are filled with neu-
rotransmitters (Katz, 1969). Synaptic 
vesicles occupy the presynaptic ter-
minal and are unusually abundant, 
so much so that the brain could be 
considered a micromolar solution of 
synaptic vesicles. Because of their 
abundance and uniform size, syn-
aptic vesicles are easy to purify and 
synaptic Vesic
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Synaptic vesicles mediate the
of Cell, Takamori et al. (2006) a
providing the most comprehenthese proteins due to polyQ expan-
sions during development could 
place adult neurons at heightened 
risk of degeneration when forced to 
deal with polyQ gain-of-function tox-
icity. For these reasons, defining the 
normal functions and interactions of 
dominant disease proteins may shed 
light upon processes of neurodegen-
eration and, perhaps, even pathways 
of cell type specificity in the CNS.
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synaptotagmins that control the trig-
gering of fusion by Ca2+. The paper 
presented in this issue by Takamori 
et al. (2006) now reports a complete 
quantitative description of the pro-
tein and lipid composition of synaptic 
vesicles, thereby confirming the stat-
ure of synaptic vesicles as a model 
organelle.
Previous work had already largely 
characterized the overall protein and 
elle  
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t nerve terminals. In this issue 
ponents of synaptic vesicles, 
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